General
Preferred name
TOLRESTAT
Synonyms
AY-27773 ()
SSR-125047 ()
AY-27,773 ()
Alderase ()
Alredase ()
P&D ID
PD009101
CAS
82964-04-3
Tags
available
drug
First approval
1989
Drug indication
diabetes mellitus
Schizophrenia
Diabetic cataract
Drug Status
approved
withdrawn
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Tolrestat is an aldose reductase inhibitor that failed Phase 3 clinical trial in the US and never made it to the clinic. The manufacturer withdrew the drug from other markets due to toxicity concerns. (GtoPdb)
DESCRIPTION Tolrestat is a potent, orally active aldose reductase inhibitor with IC50 of 35 nM.
PRICE 120
DESCRIPTION Tolrestat is an orally active and potent aldose reductase inhibitor with IC50 value of 35 nM. It was approved for the control of certain diabetic complications. It reduces RBC (red blood cells) sorbitol levels in rats. It decreased, in dose-related manner, the RBC sorbitol levels in normal and in streptozotocin diabetic rats. It failed a Phase III trial in the U.S. due to toxicity. It was discontinued by Wyeth in 1997 because of the risk of severe liver toxicity and death. It was sold under the tradename Alredase. (BOC Sciences Bioactive Compounds)
DESCRIPTION Tolrestat (AY-27773) is a potent inhibitor of aldose reductase (IC50 = 35 nM). (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
2
Compound Sets
20
AdooQ Bioactive Compound Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NPC Screening Collection
ReFrame library
TargetMol Bioactive Compound Library
Withdrawn 2.0
External IDs
79
Properties
(calculated by RDKit )
Molecular Weight
357.06
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
2
Aromatic Ring Count
2
cLogP
3.56
TPSA
49.77
Fraction CSP3
0.25
Chiral centers
0.0
Largest ring
6.0
QED
0.85
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
Aldose Reductase
AKR1A1, AKR1B1, AKR1B10
MOA
Aldose reductase inhibitor
ATC
A10XA01
Toxicity type
hepatic
Pathway
Metabolic Enzyme/Protease
Endocrinology/Hormones
Metabolism
Solubility
10 mM in DMSO
Source data